The therapeutic effect of Beta-D mannuronic acid in breast cancer patients

Evaluation of the effect of Beta-D mannuronic acid on processing of breast cancer disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017012213739N7

Enrollment

Registered

2017-02-05

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Breast cancer. Condition 2: Breast cancer. Condition 3: Breast cancer. Condition 4: Breast cancer. Condition 5: Breast cancer. Condition 6: Breast cancer. Condition 7: Breast cancer. Condition 8: Breast cancer. Malignant neoplasm: overlapping lesion of breast Malignant neoplasm: upper-inner quadrant of breast Malignant neoplasm: lower-inner quadrant of breast Malignant neoplasm: upper-outer quadrant of breast Malignant neoplasm: lower-outer quadrant of breast Malignant neoplas

Interventions

Intervention 1: The intervention group will receive 1500 mg/day (three 500 mg tablets/day) of beta-D mannuronic acid orally for 12 weeks. The beta-D mannuronic acid produced from the decomposition of

Treatment - Drugs

Control group will receive of conventional drugs orally for 12 weeks.

The intervention group will receive 1500 mg/day (three 500 mg tablets/day) of beta-D mannuronic acid orally for 12 weeks. The beta-D mannuronic acid produced from the decomposition of Alginate powder

Eligibility

Sex/Gender

Female

Age

65 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 30-60 years old patients, Diagnosed with breast cancer according to American College of oncology Diagnostic Criteria after the initial visit by a specialist in cancer surgery and parameters CEA, CA15.3, CBC and sonography, Each patient must sign written informed consent. Exclusion Criteria: History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen- vascular and auto immune diseases, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease).

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Tumor size. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Sonography.	—

Primary

Measure	Time frame
Feel the mass and tenacity in breast. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Examination by specialist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abbas Mirshafiey

Department of pathobiology, School of Public Health, Tehran University of Medical Sciences

mirshafiey@tums.ac.ir+98 21 8895 4913

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026